Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial
CardiologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- European journal of heart failure
- Publicado em
- 29 out 2025
- Citações
- 4
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial
Awais Sheikh, Zi Michael Miao, Brian Claggett, Pablo Garcia-Pavia, Francesco Cappelli, Emre Aldinc, Julian Gillmore, Scott D. Solomon, Marianna Fontana
Descritores MeSH
- Amyloid Neuropathies, Familial
- Cardiomyopathies
- Age Factors
- Aged
- Aged, 80 and over
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
Veja também
Estudos relacionados
- Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B
- Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial
- Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme
- Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis